News Article | April 20, 2017
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a regular quarterly dividend of 37.5 cents per share, an increase of 4.2 percent over the year-ago period. The dividend is payable 12 June 2017 to stockholders of record on 18 May 2017. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 338 straight quarters (more than 84 years) and have raised the dividend for 41 consecutive years. Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise. The company was created through the combination of Walgreens and Alliance Boots in December 2014, bringing together two leading companies with iconic brands, complementary geographic footprints, shared values and a heritage of trusted health care services through pharmaceutical wholesaling and community pharmacy care, dating back more than 100 years. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the USA and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25* countries and employ more than 400,000* people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which it has equity method investments, has over 13,200* stores in 11* countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with over 390* distribution centers delivering to more than 230,000** pharmacies, doctors, health centers and hospitals each year in more than 20* countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products. The company’s portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands such as No7, Botanics, Liz Earle and Soap & Glory. In October 2016 Walgreens Boots Alliance received the United Nations Foundation Global Leadership Award for its commitment to the UN’s Sustainable Development Goals. The company also ranks No. 1 in the Food and Drug Stores industry of Fortune magazine’s 2017 list of the World’s Most Admired Companies. More company information is available at www.walgreensbootsalliance.com. * As of 31 August 2016, using publicly available information for AmerisourceBergen. ** For 12 months ending 31 August 2016, using publicly available information for AmerisourceBergen. Cautionary Note Regarding Forward-Looking Statements: All statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including those described in Item 1A (Risk Factors) of our Form 10-K for the fiscal year ending 31 August 2016, which is incorporated herein by reference, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially. These forward-looking statements speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.
Moyal D.,L'Oréal |
Alard V.,LVMH Recherche |
Bertin C.,Johnson and Johnson Sante Beaute France |
Boyer F.,Pierre Fabre |
And 4 more authors.
International Journal of Cosmetic Science | Year: 2013
Synopsis A multicentred study derived from the COLIPA in vitro UVA method was performed to assess the influence of test conditions on UVA protection factor (UVAPF) values in terms of amplitude, reproducibility between laboratories and correlation with in vivo UVA results. Eight products with a range of in vivo UVAPF from three to 29 were used. Two different types of plates, namely high-roughness (5 μm) and low-roughness (2 μm) plates, were used with a different application rate for each (1.3 mg cm-2 and 0.75 mg cm-2 respectively). The UVR dose applied to both plate types followed the same principle as the original test (1.2 J. cm-2 × UVAPF0). Strong, significant correlations between in vitro and in vivo UVAPF values were observed for both plate types (Pearson correlation > 0.9, P ≤ 0.01). The correlation and slope obtained with the low-roughness plates confirmed the previous results obtained by COLIPA. Across all laboratories, higher UVAPF values were obtained on the high-roughness plates (P < 0.01). Reproducibility of UVAPF values between laboratories was comparable between the two plate roughness values (low roughness, COV = 8%; high roughness, COV = 12%). Considering the in vitro/in vivo comparisons, a regression slope of 0.83 was observed for the low-roughness plates, in comparison with a value of 1.05 for the high-roughness plates. The accuracy of the method was improved, therefore, with the use of the high-roughness plates. With a constraint to recommend the use of only one plate type in the COLIPA UVA in vitro Test, the high-roughness plate was selected on an on-going basis to limit variability of results and to provide better accuracy with in vivo data. © 2012 Society of Cosmetic Scientists.
Diffey B.L.,Newcastle University |
Brown M.W.,Alliance Boots Ltd
Photochemistry and Photobiology | Year: 2012
Sunscreens were originally designed to prevent sunburn and incorporated active ingredients that absorbed principally in the UVB region. However, over the past 20 years or so new ingredients have been developed that extend absorption across a much wider range of the solar ultraviolet spectrum in the belief that sunscreens should provide balanced spectral absorption. This article develops the rationale for spectral uniformity by showing that this requirement is aligned to more natural forms of photoprotection. It is shown that a modern sunscreen can provide a spectrally balanced absorption profile in line with shade and many types of clothing fabric. Finally, a new metric is introduced that measures how well the spectral absorption profile of topical sunscreens performs against this ideal. For two decades manufacturers have sought to develop sunscreens with spectral profiles that approach uniform absorption across the solar ultraviolet spectrum. There has been considerable success in this regard and today we have available products that virtually meet this criterion of spectral uniformity. Yet to ensure optimal compliance by consumers, sunscreens need to be colorless when applied to the skin and hence their absorbance needs to fall to zero as the nonvisible UV wavelengths merge into the visible region. This figure compares our proposed ideal spectral profile of a topical sunscreen with the spectral sensitivity of the eye. © 2012 The American Society of Photobiology.
Bradley E.J.,Alliance Boots Ltd. |
Griffiths C.E.M.,University of Manchester |
Sherratt M.J.,University of Manchester |
Bell M.,Alliance Boots Ltd. |
Watson R.E.B.,University of Manchester
Maturitas | Year: 2015
Ultraviolet radiation (UVR)-induced photoageing of the skin is associated with characteristic clinical features including a sallow complexion, deep, coarse wrinkles and a loss of elasticity. Remodelling of the dermal extracellular matrix (ECM) with changes to fibrillar collagens, elastic fibres and glycosaminoglycans is likely to be a major contributing factor to these particular clinical signs. Over-the-counter (OTC) topical formulations are one popular management strategy for preventing and/or repairing photoaged skin, most commonly targeting wrinkles as these are often the most concerning clinical feature. Due to the cosmetic nature of such formulations, evidence of their clinical efficacy and mechanism of action is often limited. However, these formulations usually contain putative active ingredients which individually have been subject to in vitro and in vivo investigation for efficacy as photoageing interventions. This review highlights commonly found ingredients within OTC formulations and assesses the evidence for: (i) their efficacy in clinically and histologically improving photoaged skin; (ii) the potential mechanisms of action; and (iii) their ability to act synergistically with complementary ingredients to enhance the clinical outcome. © 2015 Elsevier Ireland Ltd All rights reserved.